Melinta Therapeutics Provides Baxdela NDA Update
27. Februar 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...
Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA
05. Januar 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S....
Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™
26. Oktober 2016 08:00 ET
|
Melinta Therapeutics
NEW ORLEANS, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections,...
Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
24. Oktober 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has...
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
14. Juni 2016 12:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections
12. Mai 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, May 12, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results...
Melinta Therapeutics Appoints Dr. Eugene Sun as Chief Executive Officer
19. April 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, April 19, 2016 (GLOBE NEWSWIRE) -- The Board of Directors of Melinta Therapeutics today announced that Eugene Sun, M.D., has been appointed Melinta’s Chief Executive Officer and...
Melinta Therapeutics to Present at BioCentury Future Leaders Conference
03. März 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will present a clinical and...
Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer
23. Februar 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that John Temperato has joined Melinta as President and Chief Operating Officer. Prior to joining Melinta,...
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia
06. Januar 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced the initiation of an...